Jump to main content
Jump to site search

Issue 27, 2011
Previous Article Next Article

Anticancer activity of tetracationic arene ruthenium metalla-cycles

Author affiliations

Abstract

A series of cationic metalla-cycles of the general formulae [(η6-p-cym)4Ru4(OOOO)2(NN)2]4+ and [(η6-p-cym)4Ru4(NONO)2(NN)2]4+ has been prepared from the dinuclear arene ruthenium precursors [(η6-p-cym)2Ru2(OOOO)2Cl2] (OOOO = oxalato, 1,4-benzoquinonato-2,5-diolato, 1,4-naphtoquinonato-5,8-diolato, 9,10-anthraquinonato-1,4-diolato, 5,12-tetraquinonato-6,11-diolato) and [(η6-p-cym)2Ru2(NONO)2Cl2] (NONO = oxamido, oxonico) by reaction with two different bidentate linkers (NN = 1,2-bis(4-pyridyl)ethylene, 1,2-bis(4-pyridyl)ethane) in the presence of silver triflate. All complexes were isolated as triflate salts and characterised by NMR, infrared, UV-visible, mass spectrometry and by elemental analysis. The cytotoxicities of the tetranuclear ruthenium complexes have been established using ovarian A2780 and A2780cisR cancer cell lines. All complexes exhibit moderate to excellent activity on both the cisplatin resistant and cisplatin sensitive cells, thus suggesting a mode of action different from cisplatin.

Graphical abstract: Anticancer activity of tetracationic arene ruthenium metalla-cycles

Back to tab navigation

Publication details

The article was received on 23 Mar 2011, accepted on 21 Apr 2011 and first published on 09 Jun 2011


Article type: Paper
DOI: 10.1039/C1DT10489F
Dalton Trans., 2011,40, 7172-7180

  •   Request permissions

    Anticancer activity of tetracationic arene ruthenium metalla-cycles

    N. P. E. Barry, F. Edafe and B. Therrien, Dalton Trans., 2011, 40, 7172
    DOI: 10.1039/C1DT10489F

Search articles by author

Spotlight

Advertisements